elacestrant
Orserdu Approved for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
The FDA has approved elacestrant (Orserdu, Stemline Therapeutics) for postmenopausal women or adult men with ...
FEBRUARY 3, 2023
Elacestrant Shines in EMERALD Trial
In the second- and third-line post-CDK4/6 inhibitor settings, elacestrant (Radius Health) demonstrated a ...
DECEMBER 20, 2021
Load more